Federal court deals blow to Gilead and Astellas in patent case against Pfizer generic
The Court of Appeals for the Federal Circuit yesterday ruled against Astellas and Gilead in a drawn-out patent battle over the active ingredient in a Pfizer company’s generic version of Lexiscan, which is used in a cardiac stress test called myocardial perfusion imaging.
The decision is a blow for Astellas, which hauled in more than $700 million in revenue in 2021 from Lexiscan.
The loss comes as a judge in the District Court for the District of Delaware previously decided last year that Astellas had failed to prove any direct infringement and stopped the company from bringing a second infringement case to trial.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
